A Public Health Approach to the Prevention of Inhibitors in Hemophilia

J. Michael Soucie, PhD, Connie H. Miller, PhD, Fiona M. Kelly, MPH, Meredith Oakley, DVM, MPH, Deborah L. Brown, MD, and Phillip Kucab, MD
Division of Blood Disorders (Soucie, Miller, Kelly, Oakley), National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia; University of Texas Health Science Center (Brown), MD Anderson Cancer Center and Gulf States Hemophilia and Thrombophilia Treatment Center, Houston, Texas; and Wayne State University School of Medicine (Kucab), Detroit, Michigan

Abstract

The development of an antibody in people with hemophilia to products used in the treatment and prevention of bleeding, also referred to as an inhibitor, is the most serious complication of hemophilia care today. CDC, together with healthcare providers, consumer organizations, hemophilia organizations, and federal partners, has developed a public health agenda to prevent the development of inhibitors. This paper describes a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors of patients and providers, in addition to screening and treatment practices.

Introduction

The primary congenital bleeding disorders are hemophilia A and B, which are deficiencies in a protein (factor) that is necessary for normal blood clotting, and affect approximately 1 in 10,000 and 1 in 35,000 male Americans, respectively. As many as one third of patients with severe hemophilia A will develop an antibody (i.e., inhibitor) to the factor replacement products that are infused intravenously to stop or prevent a bleeding episode. Most inhibitors develop during the first few infusions with factor, which, among those with severe hemophilia, usually occur before age 2 years although all patients are at risk of developing an inhibitor. An inhibitor neutralizes a treatment product’s ability to control bleeding.

The healthcare costs associated with inhibitors are staggering. Patients with inhibitors are twice as likely to be hospitalized for a bleeding complication. In addition, compared with the cost of care for patients without an inhibitor, the cost of care for those with an inhibitor...
who have a bleeding complication is four to five times greater and, in some cases, may exceed a million dollars annually.\textsuperscript{5,6}

Improvements in clotting factor safety and efficacy over the past several decades, along with the widespread use of prophylaxis, have greatly decreased hemophilia-related morbidity and mortality. Prophylactic therapy (infusion of factor products to prevent bleeding episodes) is considered the standard of care for patients who do not have an inhibitor, and primary prophylaxis (i.e., therapy started before the second clinically evident large joint bleed and age 3 years) has been shown to decrease frequency of hemarthroses and prevent long-term joint damage.\textsuperscript{7}

Although these advancements in care and treatment have, in many cases, led to a nearly bleed-free life, this is not true for patients with an inhibitor, who continue to have bleeding episodes that require frequent and costly treatment and often take longer to resolve and, therefore, have a greater potential effect on quality of life owing to missed days at school or work.

Patients with an inhibitor have significant care management considerations beyond those without an inhibitor. Because there are fewer factor replacement choices for patients with an inhibitor, medical management often is more complex. Treatment for the inhibitor can include use of more expensive inhibitor-bypassing drugs or immune tolerance induction (ITI) therapy, which requires frequent infusion of large doses of factor products. Venous access can become difficult and may require the use of venous access devices, arteriovenous fistulas, or both.

Surgical intervention often is more complex, given limited access to surgeons with experience operating on patients with an inhibitor. The increased cost creates an additional financial burden, as well as difficulty navigating insurance options and management. Even with treatment, patients with an inhibitor are significantly more likely to die from bleeding complications than those without an inhibitor.\textsuperscript{8}

The purpose of this paper is to describe a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in the epidemiology and prevention of inhibitors in the U.S.

**Causes of Inhibitors**

Inhibitors are antibodies developed by the body’s immune system in response to an infused replacement factor. Although genetic factors, such as the $F8$ or $F9$ gene mutation and polymorphisms within certain immune system genes, are known to influence the risk of developing an inhibitor,\textsuperscript{9} environmental and treatment factors also can play a role.

For example, a cohort study\textsuperscript{10} of previously untreated patients with hemophilia followed for the first 75 exposure days at 26 European treatment centers observed that periods of “intense treatments” (in which factor replacement was given for 5 or more contiguous days) were more likely to lead to inhibitor development. Further study of other treatment-related risk factors...
factors such as product switching, continuous factor infusion, infections, and surgical or non-surgical procedures is necessary for development of better prevention strategies.

National Surveillance for Inhibitors

Hemophilia is a rare condition, affecting an estimated 22,000 male Americans. Although as many as one third of these patients might develop an inhibitor at some point, in any given year the number of new inhibitor cases is relatively small. Surveillance from the United Kingdom has found an overall incidence rate of inhibitor development among patients with severe hemophilia of 10.92 per 1,000 person-years.\(^{11}\)

Therefore, monitoring of a large proportion of the U.S. population with hemophilia will be necessary to obtain accurate measures of incidence and prevalence, effectively monitor trends in occurrence rates over time, and assess risk factors for developing inhibitors. Monitoring large numbers of patients also will be required to determine whether apparent clusters of inhibitor cases represent an actual increase that might be caused by something preventable or are just due to chance. National surveillance with centralized testing for inhibitors can provide other advantages over individual local, regional, or multisite efforts, including standardized inhibitor screening tests administered on a regular basis, confirmation of local inhibitor testing results, and consistent monitoring and reporting of national inhibitor occurrence rates.

The Role of the U.S. Hemophilia Treatment Center Network

In the early 1970s, the development of clotting factor concentrates that were effective at stopping bleeding episodes and could be administered to patients outside of a hospital setting led the U.S. Government to establish a network of specialized hemophilia treatment centers (HTCs) in 1975 in order to provide multidisciplinary care to patients with hemophilia.\(^{12}\) A population-based study\(^{1}\) in the 1990s showed that about 70% of the U.S. population with hemophilia was receiving care in these centers. Furthermore, the study showed that rates of both mortality and hospitalization for bleeding complications were lower among those receiving care in the HTCs than among those receiving care elsewhere.\(^{4,13}\)

In 1998, CDC established a surveillance system in the HTCs to monitor care practices and patient outcomes, including monitoring for product-transmitted infections.\(^{14,15}\) Although the system was not specifically designed to study inhibitors, analysis of data from the surveillance system revealed that less than one half of patients were being screened regularly for inhibitors (JMS, unpublished observations, 2013).

Because the patient and provider communities have identified inhibitors as an issue of concern, CDC has begun national surveillance for inhibitors in the HTCs, with the CDC Division of Blood Disorders laboratory providing prospective inhibitor testing using methods developed as part of a research study supported by public and private funding\(^{3,16}\) and the HTCs providing clinical expertise and data to characterize risk factors for inhibitor development.
Identification of risk factors for the development of inhibitors is necessary to avoid practices that can increase the likelihood of inhibitor development. Anecdotal reports and a single-institution case series have suggested that early prophylaxis begun in the first year of life and prior to the first joint bleed lowers the risk of inhibitor development. \(^{17}\) Avoidance of treatment with factor VIII (FVIII) replacement therapy coincident with vaccine administration has been recommended by some in order to avoid a theoretic “danger signal” that might trigger an immune response after FVIII exposure. \(^{17, 18}\)

Although most inhibitors appear before the first 50 treatments with factor replacement (exposure days), clinical trials that enrolled patients with more than 150 exposure days prior to trial entry revealed that new inhibitors might develop well beyond the first 50 exposure days. \(^{19}\) The calculated risk of inhibitor formation after 150 exposure days, based on a systematic review of 33 different studies, was estimated to be approximately 3 per 1,000 person-years. \(^{19}\)

Rarely, new inhibitors have been linked to specific factor-replacement products, and this discovery has led to a better appreciation of possible alterations of the FVIII protein that render it more immunogenic. \(^{20}\) The role of specific treatment products is very difficult to determine even when utilizing meta-analyses, because the studies use different patient populations and frequencies of inhibitor testing. Better precision from prospective monitoring will help to establish a “standard risk,” to which the risk of new products undergoing evaluation for safety in clinical trials can be compared. Many patients are reluctant to switch treatment products because of a realistic fear that a new inhibitor might emerge; however, better risk stratification will help to inform their decisions.

Inhibitors that result from a very strong immune response, called high-titer inhibitors, necessitate a change in treatment product and regimen, whereas low-titer inhibitors can be overcome by increasing the dose of FVIII. In some cases, low-titer inhibitors can be transient and disappear without change in treatment. Cross-sectional studies will not detect the majority of the transient inhibitors, and even if they are detected, it is unlikely that such an inhibitor would be correctly categorized as self-resolving.

Patients with mild hemophilia have a lower risk of inhibitor formation. However, because their exposures to treatment products more frequently are associated with surgeries, an unrecognized inhibitor could have catastrophic outcomes. Once factor replacement treatment is discontinued, inhibitors might become low titer or not detectable, which could lead to an underestimation of inhibitors among patients with mild hemophilia in cross-sectional studies or in prospective studies with very short follow-up periods. Therefore, long-term prospective monitoring can better assess the occurrence and clinical significance of inhibitors among those with mild hemophilia.

A component of the national inhibitor surveillance will be the retrospective data collection on genetic and environmental treatment–related risk factors in the previous 4-month period at the time of new inhibitor identification. Although retrospective data have limitations, collecting these data (including factor infusion logs) from all patients prospectively is not feasible given the high costs of HTC staff time for the follow-up required to ensure patient
adherence to reporting. A partnership combining the clinical expertise of the HTCs and the epidemiologic and laboratory skills of CDC is ideal for mounting an effective national surveillance program of and collecting data on treatment-related risk factors for a large American cohort to identify which treatment practices are associated with a greater likelihood of inhibitor development and, therefore, should be avoided.

The Role of a Central Laboratory

Inhibitors occurring among patients are measured by their ability to inhibit factor activity in vitro. Measurement of hemophilic inhibitors in the U.S. was standardized in 1975 at a meeting in Bethesda MD, which produced a method bearing the name of the conference site. The Bethesda assay method has persisted virtually unchanged in the majority of laboratories in the U.S. Modifications to the method—called the Nijmegen–Bethesda assay and recommended by the International Society on Thrombosis and Haemostasis—were introduced in Europe in 1995 but have not been adopted widely in the U.S.

The United Kingdom and European Union inhibitor surveillance programs rely on test results reported from local laboratories; however, proficiency testing has shown a high degree of inter-laboratory variability in results of inhibitor tests in Europe, the United Kingdom, and the U.S., which could lead to inconsistencies in the collected data. Regulatory bodies have recommended either centralized testing for inhibitors or quality control systems to monitor local laboratories as part of national registries, and CDC has concluded that centralized testing is needed initially to provide the degree of standardization required to accurately assess the prevalence and incidence of inhibitors in the U.S. hemophilia population.

The performance of large numbers of tests by a central laboratory, as piloted by CDC, will result in economies of scale, enhanced quality control, and the availability of large data sets for analysis. Reagents, such as buffered normal pooled plasma, can be prepared or purchased in bulk. Quality control testing materials, which are not available commercially, can be prepared and used consistently. Analysis of large data sets has led to the recognition of systematic testing problems and development of improvements in methods used for inhibitor measurement.

Validation of a modification to the Nijmegen–Bethesda assay for removing infused FVIII prior to inhibitor measurement has facilitated surveillance by allowing patients on prophylaxis and those recently treated to be tested without refraining from factor use. The ability to test for an inhibitor in the presence of FVIII has the potential to facilitate more complete monitoring of the hemophilia population for inhibitors. Study of large numbers of patients with a single method has allowed development of a more accurate definition of a positive inhibitor result and the addition of more sensitive and specific assays to confirm questionable results.

Although standardized methods are crucial for surveillance purposes, they also are important for clinical care to allow early detection of inhibitors and monitoring of therapy, such as ITI. Technical advances in inhibitor measurement developed at CDC will be disseminated to local laboratories used by providers of care to patients with hemophilia. This process will be
monitored by verification of local laboratory testing results by repeat testing of samples at the CDC laboratory. It is expected that dissemination of the standardized testing methods to local laboratories will increase the accuracy and efficiency of case-finding activities in the future and will facilitate the transition of the role of the CDC laboratory from the performance of centralized testing to serving as a reference laboratory for monitoring and quality control.

The Contribution of Public Health Research to Inhibitor Prevention

The public health goal of inhibitor surveillance and research is to reduce the incidence of inhibitors. In the U.S., surveillance with centralized testing will determine the magnitude of this adverse event through measurement of the incidence and prevalence of inhibitor development among patients. Inhibitor research is needed to characterize inhibitor testing among current providers, describe inhibitor characteristics and clinical outcomes, identify key genetic and environmental risk factors, and determine patient health information needs regarding inhibitors.

Public health research is needed in the U.S. to identify standardized, evidence-based intervals for inhibitor testing. Early identification of inhibitors has been correlated with increased treatment success and decreased duration of inhibitor treatment. Studies are needed to characterize provider testing practices and determine the ways in which knowledge and awareness of inhibitors can influence testing practices. Assessment of the barriers and facilitators to routine inhibitor screening will inform the development of interventions.

Public health laboratory research is needed to (1) characterize inhibitor titer levels over time; (2) investigate inhibitor characteristics, such as reactions with specific products, epitope specificity, and kinetics; and (3) correlate these characteristics with clinical outcomes, including inhibitor transience and response to ITI therapy. Data from these studies will be used to generate evidence-based, standardized definitions of both transient and clinically significant inhibitors that, in turn, will allow clinicians to provide more rapid and appropriate treatment.

Epidemiologic studies are needed to further elucidate the risks and protective factors for inhibitor development. Surveillance efforts will facilitate research efforts by providing access to the necessary large sample sizes required to examine patient immune response variations, product exposure risks, and potential protective factors for inhibitor development. The results of studies of the interactions between these genetic and environmental risk factors then can be used to develop patient-specific risk algorithms for inhibitor development.

Prevention research is needed to assess the health information needs of patients with and at risk for inhibitors and to develop interventions. Despite the fact that inhibitors have been identified as a priority issue by the hemophilia community, no studies have examined patient knowledge and awareness of inhibitors; experiences with testing, diagnosis, and treatment; and barriers and facilitators to testing and treatment. Such research is needed to develop, implement, and evaluate interventions to address these issues. Gaps in knowledge among
patients can negatively influence participation in needed research studies in the short term and can decrease the effectiveness of future inhibitor reduction strategies in the long term.

Finally, research is needed to assess the full economic effect of inhibitor development in the U.S. Current research has demonstrated that the cost to treat a single inhibitor patient can exceed $1 million dollars per year.\textsuperscript{5,6} However, little research has been done in the U.S. to document the direct inpatient, direct outpatient, and indirect costs associated with care for patients with inhibitors. The results of such research will be needed to evaluate the cost-effectiveness of future interventions and inform policy decisions regarding resource allocation.

**Conclusions**

Inhibitor development is currently one of the most important causes of morbidity for patients with hemophilia in the U.S. Prevention will require a comprehensive public health approach that includes not only surveillance, but epidemiologic, laboratory, and prevention research. Partnerships with the HTCs, consumer organizations, hemophilia organizations, and federal partners are vital to accomplishing CDC’s public health goal of preventing inhibitor development.

**References**

1. Soucie JM, Evatt B, Jackson D. The occurrence of hemophilia in the U. S Am J Hematol. 1998; 59(4):288–94.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4):418–35. [PubMed: 12828678]
3. Soucie JM, Miller CH, Kelly FM, et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the U. S Haemophilia. 2014; 20(2):230–7.
4. Soucie JM, Symons J, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001; 7(2):198–206. [PubMed: 11260280]
5. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the U.S 2008. Haemophilia. 2012; 18(2):268–75. [PubMed: 22151000]
6. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the U.S 2008. Haemophilia. 2012; 18(2):276–83. [PubMed: 22188641]
7. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535–44. [PubMed: 17687129]
8. Walsh C, Soucie JM, Miller CH. Increased mortality risk in U.S. hemophilia A inhibitor patients (abstract). J Thromb Haemost. 2013; 11(S2):475.
9. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T- lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009; 7(12):2066–15. [PubMed: 19817985]
10. Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013; 121(10): 4046–55. [PubMed: 23553768]
11. Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011; 117(23):6367–70. [PubMed: 21471523]
12. Baker JR, Crudder SO, Riske B, Bias V, Forsberg A. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health. 2005; 95(11):1910–6. [PubMed: 16195525]
13. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. Blood. 2000; 96(2):437–42. [PubMed: 10887103]
14. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med. 2010; 38(4S):S475–S481. [PubMed: 20331946]
15. CDC. Blood safety monitoring among persons with bleeding disorders—U.S. May 1998 – June 2002. MMWR Morb Mort Wkly Rep. 2003; 51(51–52):1152–4.
16. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM. The Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda Assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012; 10(6):1055–61. [PubMed: 22435927]
17. Kurnik K,Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010; 16 (2):256–62. [PubMed: 19878331]
18. Bermejo N, Martin Aguilera C, Carnicero F, Bergua J. Allergenic vaccines administration and inhibitor development in haemophilia. Haemophilia. 2012; 18(5):e392–e393. [PubMed: 22672147]
19. Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost. 2013; 11(9):1655–62. [PubMed: 23802542]
20. Rosendaal FR, Nieuwenhuis HK, Van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood. 1993; 81(8):2180–6. [PubMed: 24717777]
21. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh. 1975; 34 (3):869–72.
22. Verbruggen B, Novakova I, Wessels H, Boezeman, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 73(2):247–51. [PubMed: 7792738]
23. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost. 1998; 79(4):872–5. [PubMed: 9569207]
24. Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P. NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol. 2009; 131(4):552–8. [PubMed: 19289591]
25. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TAL, Walker ID. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK National Quality External Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2009; 35(8):778–85. [PubMed: 20169514]
26. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the External Quality Assessment Program of the ECAT Foundation. Semin Thromb Hemost. 2009; 35(8):786–93. [PubMed: 20169515]
27. European Medicines Agency. Report of expert meeting on factor VIII products and inhibitor development 28 February 2006–2 March 2006. London, UK: EMEA; 2007. www.emea.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500015512.pdf
28. Miller CH, Rice AS, Boylan B, et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the U.S. Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013; 11(7):1300–9. [PubMed: 23601690]

29. Hay CR, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6): 1335–44. [PubMed: 22101900]